In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

The safety of cardiac magnetic resonance imaging in patients with implantable cardiac devices compatible and non-compatible with MRI

Session Abstract session 4: latest advances in CMR technology and safety

Speaker Magdalena Janus

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance: Physics and Technology
  • Session type : Abstract Session
  • FP Number : 544

Authors : S Rozmiarek (Poznan,PL), J Rajewska-Tabor (Poznan,PL), A Klotzka (Poznan,PL), M Janus (Poznan,PL), A Siniawski (Poznan,PL), M Pyda (Poznan,PL)

Authors:
S Rozmiarek1 , J Rajewska-Tabor1 , A Klotzka1 , M Janus1 , A Siniawski1 , M Pyda1 , 1Poznan University of Medical Sciences, Cardiac Magnetic Resonance Unit - Poznan - Poland ,

Citation:
European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii425

Background: Lately there has been a growing number of patients with implanted electronic cardiac devices and at the same time an increase in the use of MRI. It is estimated that in the coming 10 years as many as 63% of such patients will need MRI diagnosis. Resonance imaging is however avoided in most patients with implanted cardiac devices because of the overall poorer quality of MRI and safety concerns contrary to the ESC guidelines on MRI which support use of this modality regardless of the ICD type (compatible or non-compatible with the MRI) as long as the safety protocol is observed.

Objective: To estimate the safety of cardiac magnetic resonance imaging in patients with implantable cardioverter-defibrillators (ICCD) compatible and non-compatible with MRI.

Patients and methods: 92 patients with ICD, aged 60.7 +/- 10.6 years (90% with coronary artery disease) underwent CMR examination. ICD was implanted for primary prevention in 64 patients, and in 28 patients for secondary prevention. The MRI-compatible and non-compatible devices were implanted in 50 and 42 patients, respectively.

CMR was performed on 1.5 T scanner (Magnetom Avanto, Siemens). ICD was re-programmed for the duration of MRI examination according to the 2013 ESC guidelines. The baseline settings were restored after CMR. ICD parameters were checked three times: before, immediately after and 30 days after CMR. Patients’ safety was monitored by pacing impedance, defibrillation impedance, pacing threshold and sensitivity of the detection of R wave (sensing amplitude).

Results: No device-related adverse events were documented during CMR. There were no significant differences for both MRI-compatible and MRI-non-compatible devices in terms of parameters measured before, immediately after and 30 days after CMR. The pacing impedance measured at all three timepoints showed no significant differences for both MRI-compatible (521.02? ± 113.02? vs 524.52? ± 112.06? vs 521.02? ± 111.89?; p=ns) and MRI-non-compatible devices (445.45? ± 106.95? vs 438.00? ± 104.56? vs 454.05? ± 106.18?; p =ns). Similarly, no differences in defibrillation impedance were observed for both types of devices, MRI-compatible (79.52? ± 8.35? vs 80.52? ± 8.11? vs 80.58? ± 8.07?; p=ns) and MRI-non-compatible ones ( 65.70? ± 6.62? vs 67.60? ± 6.83? vs 65.93? ± 6.77?; p = ns). Pacing threshold and sensitivity of R wave detection (sensing amplitude) were also within normal limits.

Conclusions: With appropriate precautions, CMR may be performed safely in patients with either compatible or non-compatible devices. All device parameters measured after the CMR scan for both, MRI-compatible and MRI-non-compatible devices, confirmed normal device performance.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are